Multiple myeloma

Indication for Thiotepa

Population group: Suitable for both men and women, only adults (18 years old or older)

For this indication, competent medicine agencies globally authorize below treatments:

150-250 mg/m² once a day

Route of admnistration

Intravenous

Defined daily dose

150 - 250 mg per m² of body surface area (BSA)

Dosage regimen

From 150 To 250 mg per m² of body surface area (BSA) once every day

Detailed description

Autologus haematopoietic progenitor cell transplantation

The recommended dose ranges from 150 mg/m²/day (4.05 mg/kg/day) to 250 mg/m²/day (6.76 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m² (20.27 mg/kg), during the time of the entire conditioning treatment.

Allogenic haematopoietic progenitor cell transplantation

The recommended dose is 185 mg/m²/day (5 mg/kg/day) as a single daily infusion before allogeneic HPCT, without exceeding the total maximum cumulative dose of 185 mg/m² (5 mg/kg), during the time of the entire conditioning treatment.

Dosage considerations

Thiotepa must be administered by a qualified healthcare professional as a 2-4 hours intravenous infusion via a central venous catheter.

150-250 mg/m² once a day

Route of admnistration

Intravenous

Defined daily dose

4.05 - 6.76 mg per kg of body weight

Dosage regimen

From 4.05 To 6.76 mg per kg of body weight once every day

Detailed description

Autologus haematopoietic progenitor cell transplantation

The recommended dose ranges from 150 mg/m²/day (4.05 mg/kg/day) to 250 mg/m²/day (6.76 mg/kg/day) as a single daily infusion, administered for 3 consecutive days before autologous HPCT depending on the combination with other chemotherapeutic medicinal products, without exceeding the total maximum cumulative dose of 750 mg/m² (20.27 mg/kg), during the time of the entire conditioning treatment.

Allogenic haematopoietic progenitor cell transplantation

The recommended dose is 185 mg/m²/day (5 mg/kg/day) as a single daily infusion before allogeneic HPCT, without exceeding the total maximum cumulative dose of 185 mg/m² (5 mg/kg), during the time of the entire conditioning treatment.

Dosage considerations

Thiotepa must be administered by a qualified healthcare professional as a 2-4 hours intravenous infusion via a central venous catheter.

Active ingredient

Thiotepa is a polyfunctional cytotoxic agent related chemically and pharmacologically to the nitrogen mustard. The radiomimetic action of thiotepa is believed to occur through the release of ethylene imine radicals that, as in the case of irradiation therapy, disrupt the bonds of DNA, e.g. by alkylation of guanine at the N-7, breaking the linkage between the purine base and the sugar and liberating alkylated guanine.

Read more about Thiotepa

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner